immunotherapy is well documented, there is also an increased risk of sideeffects in bee-venom-treated patients and in those with rapid dose increase. Methods: This report describes the first case of a patient in the literature with Jessner's Lymphocytic infiltration as a side effect of venom immunotherapy. This is a chronic, benign, T cell pseudolymphoma characterized by the occurrence of recurrent, asymptomatic, smooth, erythematous, non-scaling papules or plaques. However, the exact cause of Jessner's Lymphocytic Infiltration is unknown. Results: The case here reported was a 61 year-old male pediatrician, who has been followed by at our Immunology Service because of an immediate allergy to a bee sting managed with venom immunotherapy. His chief complaint was an anaphylactic reaction after 5 minutes of a bee sting. The onset of his symptoms was gradual and began just 25 minutes after the sting. The venom immunotherapy regimen was planned and the protocol immediately began without premedication. But during the initial phases of treatment, on the third dose of immunotherapy, he reported severe itching. After complaining of itching, many erythematous papules and plaques on his chest were developed. The lesions flared up for 3 days period just after injection and decreased afterwards. The type of lesions and their location supported the diagnosis of Jessner disease, which had also a histopathological confirmation. Conclusions: We herein report this case to call attention to this side effect of VIT that there may be more similar cases never reported. Medical Pharmacology, Gulhane School of Medicine, Ankara, Turkey. Background: Chemical and mechanic iritations may play causative role in development of lichenoid reactions in oral mucosa, similar to skin, in predisposed patients. It has recently been reported that lichenoid reactions and Wickham striae with papular/reticular characteristics are observed in mucosal regions which are in direct contact with amalgam restorations (1). A 38-year-old male patient admitted initially to the Department of Oral Diagnosis and Radiology, chiefly complaining of bilateral buccal pain and itching. In his intraoral inspection, hyperkeratotic white lesions at his molar teeth level at both right and left buccal mucosa were observed. The purpose of this study is to find out the nature and decide on the management of these buccal lesions. Methods: In dental inspection of the patient, large amalgam restorations and white lesions in buccal surface in direct contact with amalgam were observed in left first and second, and right second molar teeth region. A 4-mm punch biopsy from buccal mucosa was performed. In addition, a skin patch test with amalgam was done in back region of the patient. Results: In punch biopsy, histopathological features were compatible with lichenoid mucositis. In addition, skin patch test results indicated a very strong positive reaction to amalgam. The lesion healed up after replacement of restorations with composite filling material. The patient, his family and his dental practitioner were strictly advised to use alternative restorative materials in case of a need for restoration. Conclusions: Amalgam and its components may cause type IV hypersensitivity reactions (1) and, very unusually, immediate hypersensitivity (2). The clinician should be aware of all possible pathological etiologies of white lesions. If there is any doubt about the diagnosis and management of an anusual oral lesion, referral to appropriate specialists is mandatory.
Medical Pharmacology, Gulhane School of Medicine, Ankara, Turkey. Background: Chemical and mechanic iritations may play causative role in development of lichenoid reactions in oral mucosa, similar to skin, in predisposed patients. It has recently been reported that lichenoid reactions and Wickham striae with papular/reticular characteristics are observed in mucosal regions which are in direct contact with amalgam restorations (1) . A 38-year-old male patient admitted initially to the Department of Oral Diagnosis and Radiology, chiefly complaining of bilateral buccal pain and itching. In his intraoral inspection, hyperkeratotic white lesions at his molar teeth level at both right and left buccal mucosa were observed. The purpose of this study is to find out the nature and decide on the management of these buccal lesions. Methods: In dental inspection of the patient, large amalgam restorations and white lesions in buccal surface in direct contact with amalgam were observed in left first and second, and right second molar teeth region. A 4-mm punch biopsy from buccal mucosa was performed. In addition, a skin patch test with amalgam was done in back region of the patient. Results: In punch biopsy, histopathological features were compatible with lichenoid mucositis. In addition, skin patch test results indicated a very strong positive reaction to amalgam. The lesion healed up after replacement of restorations with composite filling material. The patient, his family and his dental practitioner were strictly advised to use alternative restorative materials in case of a need for restoration. Conclusions: Amalgam and its components may cause type IV hypersensitivity reactions (1) and, very unusually, immediate hypersensitivity (2) . The clinician should be aware of all possible pathological etiologies of white lesions. If there is any doubt about the diagnosis and management of an anusual oral lesion, referral to appropriate specialists is mandatory.
Ioannis Sidiropoulos, MD, Athanasios Beltsis, MD, Elena Gigi, MD, Anna Sykla, MD, Aristea Bellou, MD, and Maria Raptopoulou-Gigi, MD. Allergy, Ippokration Hospital, Thessaloniki, Greece. Background: BA Interferon (IFN)-based therapy for chronic hepatitis C (CHC) is associated with adverse hypersensitivity reactions (HRs). However, data on HRs to IFN in every-day clinical practice are lacking. We conducted a retrospective study to identify the incidence, management and outcome of such reactions. Methods: A review of the electronic files of all CHC patients followed in our tertiary referral center from January 1990 to November 2010 was conducted to identify patients submitted to IFN-based treatment and HRs to such treatment. Results: During the study period, 832 CHC patients were identified, 545 (65.5%) of whom received IFN-based treatment. Overall, 221 (40.5%) patients received at least one treatment cycle with IFN-a 6 ribavirin (RBV), 170 (31.2%) patients received at least one treatment cycle with pegylated (PEG)-IFN a2a 1 RBV and 189 (34.7%) patients received at least one treatment cycle with PEG-IFN a2b 1 RBV. Fifty-five treatment cycles were complicated by HRs in 54 patients (female 20, median age 39 years, range 22-65 years). Presenting symptoms of HRs were: skin rash in 46 patients (pruritic in 20), generalized pruritus in 7 patients and aphthous mucosal ulcers in 2 patients. HRs occurred in 9 patients treated with IFN-a (4.1%), 23 patients treated with PEG-IFN a2a (13.5%) and 23 patients treated with PEG-IFN a2b (12.1%) (P ¼ 0.002). Management of HRs included no intervention in 18 (32.7%) cases, topical treatment in 10 (18.2%) cases, antihistamine administration in 15 (27.3%) cases, temporary cessation of treatment or dose reduction in 3 (5.5%) cases, switch from PEG-IFN to IFN-a in 4 (7.3%) cases and immediate termination of treatment in 5 (9.1%) cases. The outcome was complete remission of the HR in 33 (60%) cases, remission sufficient to allow continuation of treatment in 13 (23.6%) cases and treatment termination in 8 (14.5%) cases, while one (1.8%) patient was lost to follow-up after the HR. Overall, 2 (0.9%) patients discontinued IFN-a, 3 (1.8%) PEG-IFN a2a and 3 (1.6%) PEG-IFN a2b due to HRs (P ¼ 0.737). Conclusions: Hypersensitivity reactions to IFN-based and especially to PEG-IFN based treatment regimens are occasionally encountered in CHC patients and may rarely lead to treatment termination.
DRUG ALLERGY 2
387 Hypersensitivity Syndrome Associated with Phenytoin Sodium Elizabeth Mendieta. Mexico City, Mexico. Background: The drug-induced hypersensitivity syndrome (DIHS) is a systemic reaction for drug-induced idiosyncratic. We report 1 in 1000 to 1 in 10,000 exposures to aromatic anticonvulsant. In the case of phenytoin is estimated at 2.3 to 4.5 per 10,000 exposures. There is a deficit of microsomal epoxide hydroxylase causing accumulation of toxic metabolites. Occurs between 2 weeks to 3 months after drug exposure; it is characterized by maculopapular rash, erythema midface, fever, lymphadenopathy, with alteration of the hematologic system with eosinophilia, peripheral or atypical lymphocytosis. Described reactivation of herpes virus (HHV-6 and 7).
